Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5952372 | GALDERMA LABS LP | Method for treating rosacea using oral or topical ivermectin |
Sep, 2018
(5 years ago) | |
US6133310 | GALDERMA LABS LP | Method of treatment of rosacea |
Apr, 2019
(5 years ago) | |
US7550440 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(5 days ago) | |
US8815816 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(5 days ago) | |
US8093219 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(5 days ago) | |
US8080530 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(5 days ago) | |
US8415311 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(5 days ago) | |
US11033565 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(5 days ago) | |
US8470788 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(5 days ago) | |
US9089587 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
US9233118 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
US9233117 | GALDERMA LABS LP | Treatment of inflammatory lesions of rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
US10206939 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
US9782425 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) |
Soolantra is owned by Galderma Labs Lp.
Soolantra contains Ivermectin.
Soolantra has a total of 14 drug patents out of which 9 drug patents have expired.
Expired drug patents of Soolantra are:
Soolantra was authorised for market use on 19 December, 2014.
Soolantra is available in cream;topical dosage forms.
Soolantra can be used as treatment of inflammatory lesions of rosacea..
The generics of Soolantra are possible to be released after 13 March, 2034.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 19, 2017 |
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: CREAM;TOPICAL